Group 1: BYD Company Limited (1211 HK) - The company reported revenue of CNY 237.7 billion and net profit of CNY 9.29 billion for Q4 2025, with a gross margin under pressure at 17.4% due to industry competition, but strict cost control ensured a solid profit base [1] - Future growth is expected to be driven by the new generation of hybrid technology and ramping up production capacity overseas in Southeast Asia, Latin America, and Europe, enhancing profit margins [1] - The target price has been raised to HKD 138.53, reflecting a potential upside of 30.9%, with EPS forecasts for 2026-27 increased by 7.1% and 8.8% respectively [1] Group 2: China National Heavy Duty Truck Group (3808 HK) - The company achieved revenue of CNY 58.7 billion in the second half of 2025, a year-on-year increase of 27%, and net profit of CNY 3.59 billion, up 40% year-on-year, with a significant reduction in expense ratio to 8.4% [3] - Geopolitical uncertainties have increased demand for land transportation in the Middle East, coupled with the cost-performance advantage of domestic heavy trucks, serving as core growth catalysts [3] - The target price has been raised to HKD 45.80, maintaining a buy rating, with expectations for profits to reach CNY 8.6 billion in 2026 [3] Group 3: Weichai Power Co., Ltd. (2338 HK) - The company faced short-term pressure on earnings due to main business concessions and impairments, but the underlying profit structure has significantly improved [4] - High-margin large bore engines and a surge in sales of AIDC-compatible power sources have demonstrated strong pricing power, with North American orders extending to 2028 [4] - The target price has been adjusted to HKD 31.30, maintaining a buy rating as the company transitions from a traditional commercial vehicle cycle stock to a global core supplier of power sources [4] Group 4: EVE Energy Co., Ltd. (300014 CH) - The company reported a revenue of CNY 61.47 billion for 2025, a year-on-year increase of 26.4%, with a net profit of CNY 4.13 billion, up 1.4% year-on-year [6] - The fourth quarter saw improved profitability due to increased capacity utilization and price increases for certain energy storage products, with gross and net profit margins at 16.8% and 8.0% respectively [6] - The target price remains at CNY 94.74, with a buy rating, as the company accelerates overseas capacity expansion [6] Group 5: Great Wall Motors (2333 HK) - The company achieved revenue of CNY 222.82 billion in 2025, a year-on-year increase of 10.2%, but net profit fell to CNY 9.87 billion, down 22.1% year-on-year due to increased marketing expenses [7] - The launch of the AI "Guiyuan" platform and ramping up production at the Brazil factory are expected to drive performance recovery in 2026 [7] - The target price has been lowered to HKD 17.50, maintaining a buy rating due to the company's strong pricing power in the off-road segment [7] Group 6: Rongchang Biopharmaceutical (9995 HK) - The company is expected to achieve breakeven in 2026, with product sales revenue for 2025 projected to increase by 35.8% to CNY 2.307 billion [8] - The sales of key products like Taitasip and Vidisizumab are expected to contribute significantly to revenue growth, with management forecasting over 25% growth in 2026 [8] - The target price is set at HKD 136.00, maintaining a buy rating as the company rapidly iterates its technology pipeline [8] Group 7: Innovent Biologics (1801 HK) - The company reported a 45% year-on-year increase in product revenue to CNY 11.9 billion for 2025, with the addition of seven innovative drug products [10] - The sales of the drug Ma Shidu Peptide are expected to reach CNY 1.8 billion in 2026, becoming a key growth driver [10] - The target price is set at HKD 105.00, maintaining a buy rating as the company expands its commercial product portfolio [10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock over the next six months [11]. Core Insights - The company reported a revenue of 3.056 billion yuan for 2025, representing a year-on-year growth of 43.9%, with commercial sales revenue increasing by 51.5% [2][3]. - The inclusion of two innovative dual-antibody drugs, Cardunili and Ivorosi, in the national medical insurance directory has significantly boosted sales [2][3]. - The company has expanded its sales team to approximately 1,300 personnel, focusing on oncology and specialty drugs [3]. - Clinical data for core products continues to validate their global competitiveness, with Ivorosi achieving significant results in lung cancer treatment [3]. - The company is advancing its "IO2.0 + ADC2.0" strategy, with new products in the autoimmune metabolism field and ongoing clinical trials for next-generation ADC drugs [4]. Financial Summary - The company expects revenues of 5.161 billion yuan, 7.106 billion yuan, and 8.752 billion yuan for 2026, 2027, and 2028, respectively, with net profits projected at 244 million yuan, 1.111 billion yuan, and 1.569 billion yuan [4][6]. - The EBITDA loss for 2025 was 192 million yuan, a reduction from 241 million yuan in the previous year [2][3]. - The company’s gross margin is expected to improve, reaching 82.0% by 2028 [12].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][5] Core Viewpoints - The report emphasizes the importance of the PD1 plus track, highlighting numerous catalysts and opportunities within this segment. It suggests a focus on price increase expectations and the strong fundamentals of innovative drugs, indicating a favorable risk-reward ratio for certain stocks [3][5][44] - The report outlines a two-dimensional investment framework for the year, focusing on "technology innovation leadership" and "performance/valuation recovery" [6][25][44] Summary by Sections 1. Focus on Domestic Second-Generation PD1 Progress - Kangfang Biopharma's AK112 is expected to read out key clinical data for NSCLC in 2026, with global registration clinical trials accelerating [8][9] 2. Industry Viewpoints - The pharmaceutical index has shown a decline of 0.22% from March 9 to March 13, with a relative underperformance of -0.41% compared to the CSI 300 index. Notable stock performances include Yingke Medical (+35.18%) and Zhonghong Medical (+25.26%) [5][25][26] - The report identifies several companies to watch, including Heng Rui Medicine, Xin Li Tai, and Junshi Biosciences, among others, for their strong fundamentals and growth potential [5][47] 3. Investment Recommendations - The report suggests a focus on innovative drugs, AI medical technology, and surgical robots, with specific companies highlighted for their potential in these areas [44][46] - Recommendations for March include Heng Rui Medicine, Xin Li Tai, and others, while a weekly focus includes Kangfang Biopharma and Shanghai Yizhong [47]

Group 1 - The Hong Kong stock market for innovative drugs is showing signs of recovery, with the Hong Kong Stock Connect Innovative Drug ETF (159570) experiencing a slight increase of 0.06% and a trading volume exceeding 800 million CNY [1] - The ETF has seen a net inflow of over 18 million CNY yesterday and an additional 6 million CNY today, bringing its total scale to over 23.8 billion CNY, leading in its category [1] - Key stocks within the ETF have mixed performances, with notable gains from CSPC Pharmaceutical Group (up over 3%) and BeiGene (up over 2%), while Kangji Medical and 3SBio saw declines of over 5% and nearly 3%, respectively [1][2] Group 2 - AstraZeneca plans to invest over 100 billion CNY (approximately 15 billion USD) in China by 2030, focusing on expanding its drug production and R&D capabilities, particularly in cell therapy and radiolabeled drugs [3] - AstraZeneca has entered a strategic collaboration with CSPC Pharmaceutical Group in the weight management sector, involving a total potential deal value exceeding 25 billion USD, including a 1.2 billion USD upfront payment [4] - The FDA has accepted the Biologics License Application (BLA) for the innovative drug Ivosidenib, marking a significant step for Kangji Medical in expanding its global market presence [5] Group 3 - Recent market trends indicate a decline in overall risk appetite, with innovative drugs and hard technology entering a phase of valuation adjustment and expectation reshaping [6] - By 2025, the funding levels for Chinese pharmaceutical companies are expected to increase significantly, with a projected 145% year-on-year growth in IPO fundraising and a 185.9% increase in potential milestone payments from business development [7] - The new business model for external business development (BD) is expected to benefit early-stage research projects, enhancing the return on investment for R&D and driving growth in the early research industry chain [8]

Investment Rating - The report assigns an investment rating of "Outperform" for the pharmaceutical sector, indicating a relative performance better than the market index [2]. Core Insights - The pharmaceutical sector experienced a market adjustment with the SW Pharmaceutical Biotechnology Index declining by 3.31% during the week of January 26 to February 1, 2026, underperforming the CSI 300 Index which increased by 0.08% [2]. - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030, focusing on drug production and R&D, aligning with the "Healthy China 2030" initiative [2]. - The FDA has accepted the overseas listing application for the innovative PD-1/VEGF dual antibody, Ivoris, marking a significant step in global market expansion for Chinese innovations [2]. Summary by Sections Market Performance - The pharmaceutical sector's performance was mixed, with blood products and vaccines showing relative strength, while offline pharmacies and hospitals faced declines of 4.83% and 4.47%, respectively [2]. Investment Opportunities - The report highlights continued optimism for Chinese innovative drugs going global, particularly in areas such as ADCs, dual antibodies, small nucleic acids, and weight loss drugs [2]. - Key companies to watch include InnoCare Pharma, 3SBio, WuXi AppTec, Maiwei Biotech, Kelun-Biotech, and CanSino Biologics [2]. Strategic Collaborations - AstraZeneca's collaboration with CSPC Pharmaceutical Group involves a strategic partnership in weight management, with potential milestone payments reaching up to 17.3 billion USD [2]. - The report emphasizes the importance of upcoming data updates from major conferences like JPM and ASCO for investment catalysts [2].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of February 1, 2026 [1] Core Insights - The competitiveness of China's active pharmaceutical ingredient (API) exports is supported by technological advancements, with a focus on supply variables [2] - Significant transactions in the industry highlight the ongoing validation of clinical data for innovative drugs, with multiple major deals occurring in early 2026 [3] - Leading companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [4] - A new pricing system for GLP-1 drugs is forming domestically, while the oral GLP-1 market is rapidly expanding in the U.S. [5] - The market value of oral autoimmune drugs is gaining attention, with promising results from key clinical trials [6] Summary by Sections Industry Overview - In 2025, China's pharmaceutical and healthcare product exports reached $111.34 billion, growing by 3.14%, with API exports accounting for $42.87 billion, representing 76.8% of total Western medicine exports [2] - The report notes a 10.6% decline in pharmaceutical exports to the U.S. due to tariff impacts, while the EU and emerging markets saw increases of 11.38% and 4.49%, respectively [2] Major Transactions and Innovations - In January 2026, a significant licensing agreement between CSPC Pharmaceutical and AstraZeneca was announced, involving a $1.2 billion upfront payment and potential milestone payments totaling up to $3.5 billion [3] - The report emphasizes the need for continuous clinical data validation for authorized products to secure future milestone payments [3] Small Nucleic Acid Developments - Leading companies like China Biologic Products are acquiring innovative firms in the small interfering RNA (siRNA) sector, indicating a strategic focus on this area [4] - The report highlights successful clinical trial results for small nucleic acid drugs, which are attracting more attention from major pharmaceutical companies [4] GLP-1 Market Dynamics - A new pricing structure for GLP-1 products is emerging in China, with the anticipated launch of generic versions expected to further influence market prices [5] - The report notes that oral GLP-1 drugs are gaining traction in the U.S., with significant prescription numbers reported shortly after launch [5] Oral Autoimmune Drug Developments - Takeda's new oral TYK2 inhibitor has shown positive results in key clinical trials for psoriasis, indicating a potential breakthrough in oral autoimmune treatments [6] - The report mentions ongoing developments in oral autoimmune drugs targeting various pathways, with several domestic companies advancing their clinical trials [6] Stock Recommendations - The report suggests focusing on companies that are likely to benefit from the API cycle reversal, such as Chuan Ning Biological and Guobang Pharmaceutical, and highlights the potential of small nucleic acid drugs and oral autoimmune treatments [8]

Group 1 - The Hong Kong Innovation Drug ETF (159570) has seen a significant inflow of funds, with a recent trading volume exceeding 5 billion yuan and a net inflow of over 300 million yuan in the past five days [1] - As of January 20, the total size of the Hong Kong Innovation Drug ETF reached over 25.3 billion yuan, leading the market in terms of scale among innovation drug ETFs [1] - The index components of the ETF showed mixed performance, with notable gains from companies like Kingsoft Biotech and China Biologic Products, while companies like CanSino Biologics experienced declines [3][4] Group 2 - At the J.P. Morgan Healthcare Conference, several Chinese pharmaceutical companies showcased their advancements, including BeiGene's new drug approval in China and plans for accelerated approval in the U.S. [5] - Innovent Biologics and Pfizer are set to conduct five global Phase III trials for their drug SSGJ-707 by 2026, targeting various cancers [6] - The collaboration between NVIDIA and Eli Lilly aims to establish an AI innovation lab with a projected investment of up to 1 billion USD over five years, potentially transforming drug development processes [8] Group 3 - Tempus AI reported a revenue of approximately 1.27 billion USD for 2025, marking an 83% year-on-year increase, driven by significant growth in its diagnostic business [9] - The top ten components of the Hong Kong Innovation Drug ETF account for over 73% of its weight, highlighting the concentration of leading innovative drug companies within the ETF [10]

Investment Rating - The report indicates a strong investment opportunity for Rongchang Biopharma following the signing of a significant licensing agreement with AbbVie, which is expected to enhance the company's financial position and market presence [2][25]. Core Insights - Rongchang Biopharma has signed an exclusive licensing agreement with AbbVie for the novel PD-1/VEGF bispecific antibody drug RC148, which includes an upfront payment of $650 million (approximately 4.5 billion RMB) and potential milestone payments totaling up to $4.95 billion (approximately 34.5 billion RMB) [2][8]. - The total transaction value is close to $4 billion, marking a record for the company in terms of external licensing agreements [3][8]. - The PD-1/VEGF bispecific antibody market is identified as a "golden track" for Chinese innovative drugs going global, with increasing upfront payments reflecting the growing value of these assets [9][10]. Industry Overview - The number of BD licensing deals for Chinese innovative drugs has surged from 85 in 2023 to 157 in 2025, with a compound annual growth rate of 35.9% [11]. - The total transaction value for these deals has skyrocketed from $32 billion in 2023 to $135.7 billion in 2025, representing a growth of over three times [13]. - The industry is entering an accelerated growth phase, with a year-on-year growth rate of 161% for BD licensing deals in 2025, significantly outpacing previous years [15]. Financial Performance - Rongchang Biopharma's revenue for the first three quarters of 2025 reached 1.72 billion RMB, reflecting a year-on-year increase of 42.27% [16]. - Despite ongoing net losses exceeding 1 billion RMB from 2022 to 2024, the company has shown improvement, with losses narrowing to 551 million RMB in the first three quarters of 2025 compared to 1.071 billion RMB in the same period of 2024 [17][19]. - The anticipated upfront payment from the AbbVie deal is expected to further improve Rongchang Biopharma's profitability and cash reserves, potentially leading to profitability in 2026 if the payment is fully received [19]. Product Pipeline - Rongchang Biopharma's key products include Taitasip (IL-4Rα antibody) and Vidisicimab (HER2 ADC), which are currently the main sources of revenue [20]. - The RC148 bispecific antibody is a focus for the company, currently in I/II clinical stages, and the collaboration with AbbVie is expected to accelerate its global development [23].

Core Viewpoint - Kangfang Biopharma's innovative PD-1/VEGF dual antibody, Ivosidenib, has submitted a Biologics License Application (BLA) to the FDA for treating EGFR mutation non-squamous non-small cell lung cancer (NSCLC) [1] Group 1: Company Developments - Ivosidenib's BLA submission is based on the overall results of the global Phase III HARMONi trial [1] - The application was submitted by Summit Therapeutics, the overseas partner of Kangfang Biopharma [1] Group 2: Regulatory Timeline - The FDA is expected to make a review decision on the BLA by the fourth quarter of 2026 [1] - The BLA aims to support the use of Ivosidenib in combination with chemotherapy for patients with EGFR mutation NSCLC who have progressed after third-generation EGFR-TKI treatment [1]

Core Insights - The new medical insurance directory has entered a substantial implementation phase, with multiple innovative drugs, including Tislelizumab and Fuzhengzhu, being covered by insurance in various hospitals, indicating a rapid reduction in access barriers for patients [1][3] - The adjustment includes 114 new drugs and introduces a commercial health insurance innovative drug directory for 2025, marking a significant shift towards a multi-tiered insurance payment system [1][3] Group 1: Innovative Drug Inclusion - The new medical insurance directory reflects increased support for "true innovation" with 124 unique products included, showcasing a strong emphasis on high clinical value [3][4] - Notable drugs like Tislelizumab, the first targeted therapy for thyroid eye disease, and Fuzhengzhu, a biological agent for psoriasis, have been rapidly integrated into the insurance system, filling long-standing treatment gaps [3][4] - Heng Rui Medicine is highlighted as a major beneficiary, with 20 products and indications adjusted, including 10 new drugs, enhancing patient access to innovative therapies [3][4] Group 2: Biotech Sector Impact - Companies like BeiGene, Innovent Biologics, and Kangfang Biotech are also benefiting from the new directory, accelerating their commercialization processes [4] - BeiGene is the only company with two products included in the first commercial insurance innovative drug directory, addressing unmet needs in cholangiocarcinoma and neuroblastoma [4] - Innovent Biologics has expanded its offerings to 12 innovative drugs under the new directory, creating a robust product matrix [4] Group 3: Shift in R&D Strategies - The introduction of the commercial insurance innovative drug directory is seen as a solution to the payment challenges faced by high-value innovative drugs, encouraging companies to focus on true innovation rather than me-too products [5][6] - The directory allows for a second market for high-priced therapies, with price reductions between 15% and 50%, which is less severe than the typical cuts seen in basic insurance [6][7] - This dual-directory model is expected to drive pharmaceutical companies to align their R&D strategies with real-world clinical needs, particularly in oncology and rare diseases [7][9] Group 4: Drug Exclusions - The adjustment also involved the removal of 29 drugs from the insurance directory, including Benalutide injection, which faced competition from more effective alternatives [8][9] - This "one in, one out" approach aims to enhance the efficiency of insurance fund usage by prioritizing high-demand and effective medications [9]